Ascendis Pharma A/S (ASND): A Bull Case Theory

We came across a bullish thesis on Ascendis Pharma A/S on Tip Ranks’ YouTube Channel. In this article, we will summarize the bulls’ thesis on ASND. Ascendis Pharma A/S’s share was trading at $215.05 as of January 13th. ASND’s forward P/E was 48.78, according to Yahoo Finance.

Ascendis Pharma (ASND) is a biopharma company specializing in innovative therapies for rare diseases, leveraging its proprietary Transcon technology platform to create long-acting prodrugs that improve dosing efficacy and patient compliance.

The company focuses primarily on endocrinology rare diseases, with key pipeline candidates including Transcon HDH for growth hormone deficiency, PTH for hypothyroidism, and CNP for achondroplasia, while also pursuing programs in oncology and ophthalmology. This patient-centered, science-driven approach positions Ascendis to build a fully integrated biopharma company targeting significant unmet medical needs.

The stock has appreciated 47% over the past year and is up 2.6% in the last three months, reflecting growing investor confidence. Recent trial data for Transcon CNP demonstrated higher annualized growth velocity at week 52 compared to placebo, along with improvements in lower limb alignment, body proportionality, and health-related quality of life, further highlighting the commercial and clinical potential of their pipeline. Speculation around potential takeover interest has also attracted attention.

Despite reporting a wider-than-expected quarterly loss of $1.17 per share, revenue totaled €213 million, driven by €143 million from Yorvapath and over €50 million from Sky Tropha, with a modest Q3 operating profit of €1 million.

Analyst coverage remains highly supportive, with all 15 analysts rating the stock as a buy and an average price target of $263, implying over 32% upside. Recent ratings indicate potential upside ranging from 10% to 53%, suggesting that Ascendis Pharma offers a compelling investment opportunity, underpinned by a strong pipeline, robust clinical validation, and significant market appreciation potential.

Previously we covered a bullish thesis on Capricor Therapeutics, Inc. (CAPR) by androidmj in March 2025, which highlighted the FDA decision on Deramiocel, strong financials, and upside from milestone payments and a Priority Review Voucher. The stock’s price has appreciated approximately 95.96% since our coverage. TipRanks shares a similar bullish view but emphasizes Ascendis Pharma’s Transcon platform, rare disease pipeline, recent trial successes, and analyst-backed upside potential.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.